Volume 8, Number 5—May 2002
Research
Nasopharyngeal Carriage of Streptococcus pneumoniae in Healthy Children: Implications for the Use of Heptavalent Pnemococcal Conjugate Vaccine
Paola Marchisio*, Susanna Esposito*, Gian Carlo Schito†, Anna Marchese†, Roberta Cavagna*, Nicola Principi*
, and the Hercules Project Collaborative Group
, and the Hercules Project Collaborative Group
Table 4
Univariate analysis of the variables potentially associated with the nasopharyngeal carriage of Streptococcus pneumoniae
| Total carriers | Carriers of invasive strains | Carriers of strains covered by the heptavalent vaccine | ||||
|---|---|---|---|---|---|---|
| Risk factor | ORsa | 95% CIb | ORs | 95% CI | ORs | 95% CI |
| Sex | 1.0 | 0.8-1.4 | 0.9 | 0.7-1.4 | 0.9 | 0.7-1.3 |
| Age, yrs | ||||||
| 2-5 >5 | 0.7 1.5 | 0.1-1.7 0.9-2.5 | 1.3 0.9 | 0.8-2.3 0.5-1.6 | 1.5 1.1 | 0.9-2.7 0.6-1.9 |
| Breast-feeding ≥3 mo. | 0.9 | 0.6-1.4 | 1.0 | 0.6-1.7 | 1.1 | 0.7-1.7 |
| Urban residence | 0.8 | 0.1-2.2 | 1.2 | 0.6-2.6 | 1.5 | 0.7-2.9 |
| Full-time day-care attendance | 0.4 | 0.1-1.5 | 0.8 | 0.6-1.2 | 1.0 | 0.7-1.4 |
| Child-care center ≥20 subjects | 0.9 | 0.6-1.3 | 1.2 | 0.8-1.9 | 1.2 | 0.8-1.9 |
| At least one sibling | 0.9 | 0.7-1.3 | 0.7 | 0.4-1.2 | 0.7 | 0.4-1.3 |
| First-born | 1.0 | 0.8-1.4 | 1.1 | 0.8-1.6 | 1.1 | 0.8-1.6 |
| Passive smoking | 1.0 | 0.7-1.3 | 1.0 | 0.7-1.4 | 1.0 | 0.7-1.4 |
| At least one URTIscin the previous 3 mo. | ||||||
| Rhinitis | 0.9 | 0.7-1.3 | 1.0 | 0.7-1.5 | 1.0 | 0.7-1.5 |
| Tonsillitis | 0.8 | 0.6-1.3 | 0.9 | 0.6-1.5 | 1.0 | 0.6-1.5 |
| Laryngitis | 0.6 | 0.3-1.1 | 0.8 | 0.5-1.5 | 0.8 | 0.4-1.5 |
| Acute otitis media | 1.3 | 0.9-1.9 | 1.5 | 0.9-2.3 | 1.4 | 0.9-2.2 |
| Acute sinusitis | 2.3 | 1.1-4.6d | 3.1 | 1.4-6.d | 3.3 | 1.6-6.9 d |
| LRTIse in the previous 3 mo. | ||||||
| Acute bronchitis | 0.7 | 0.4-1.1 | 0.6 | 0.3-1.1 | 0.6 | 0.4-1.1 |
| Pneumonia | 0.8 | 0.2-2.6 | 0.4 | 0.1-3.1 | 0.9 | 0.2-3.7 |
| Antibiotic therapy in the previous 3 mo. | ||||||
| Aminopenicillins | 0.9 | 0.6-1.5 | 1.0 | 0.5-1.8 | 1.0 | 0.5-1.8 |
| Amoxicillin-clavulanate | 0.8 | 0.4-1.3 | 0.7 | 0.3-1.5 | 0.8 | 0.4-1.5 |
| Macrolides | 0.6 | 0.3-1.1 | 0.8 | 0.4-1.6 | 0.7 | 0.4-1.5 |
| Cephalosporins | 0.9 | 0.6-1.3 | 0.8 | 0.5-1.3 | 0.9 | 0.6-1.5 |
| At least one antibiotic |
0.8 |
0.7-1.2 |
1.0 |
0.7-1.4 |
1.0 |
0.7-1.4 |
| aOR = odds ratio. b CI=95% confidence interval. c URTIs= upper respiratory tract infections. d p<0.05. e LRTIs=lower respiratory tract infections. | ||||||
1The Hercules Project Collaborative Group includes: F. Schettini, D. De Mattia (Bari, Italy); G. P. Salvioli, G. Faldella (Bologna, Italy); G. Caramia, E. Ruffini (Ancona, Italy); E. Reali (Cinisello Balsamo, Italy); R. Longhi (Como, Italy); G. Bona (Novara, Italy); A. Guarino, F. Albano (Napoli, Italy); R. Malvicini (Fidenza, Italy); L. Ziino (Palermo, Italy); I. Barberi, T. Corona (Messina, Italy); P. Pusceddu (Cagliari, Italy); T. Meloni (Sassari, Italy); G. Saggese, and M. Migliaccio (Pisa, Italy).
Page created: April 18, 2012
Page updated: April 18, 2012
Page reviewed: April 18, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.